Week Ending August 1, 2022

COVID or Lung Cancer? The Importance of Listening to Your Body
“While we’re still dealing with the pandemic, it’s fairly common to associate any signs of health abnormality with COVID, even months after you’ve had the virus, but there are some warning signs that may be an indication of lung cancer.”

World Lung Cancer Day: New therapies, novel combinations confer benefit
“World Lung Cancer Day will be held Aug. 1.”

Exploring Subset Analyses in the EMPOWER-Lung 1 Trial for NSCLC
“During a live virtual event, Martin F. Dietrich, MD, PhD, discussed the results of the EMPOWER-Lung 1 and EMPOWER-Lung 3 trials of cemiplimab for non–small cell lung cancer. This is the second of 2 articles based on this event.”

Addressing mental health in patients with lung cancer improves outcomes
“Mental health plays a significant role in overall health, and addressing these concerns is no less important in patients with lung cancer, according to experts.”

City of Hope approved for $7 million for lung cancer study in older adults
“The five-year, multisite study will look at how physical activity before and after surgery affects recovery in an older patient population”

Rybrevant in Combination with Lazertinib Shows Promise in Non–Small Cell Lung Cancer
“The findings of the phase 1b/2 CHRYSALIS-2 cohort will be presented at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer.”

Who might better benefit from KRAS and PD-1 combos? New Mirati drug study offers a clue
“Immune checkpoint inhibitors such as anti-PD-1 therapies, which work by unleashing T cells’ anti-tumor power, have become a standard of care for non-small cell lung cancer. Targeted therapies have also served as powerful tools against cancers bearing specific genetic alterations. But resistance may develop against both types of therapies, so scientists and drugmakers have been considering pairing them up.”

Sequential Maintenance in Extensive-Stage Small-Cell Lung Cancer
”Title: Sequential maintenance with thoracic radiotherapy and durvalumab (MEDI4736) monotherapy or durvalumab (MEDI4736) combinations (tremelimumab or olaparib) in patients with extensive stage-small cell lung cancer after first line platinum based chemotherapy”

Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 Expression

Targeting KRAS Mutations in Lung Cancer
– ASCO Reading Room video analysis with thought leader James Stevenson, MD

Educated Patient® Lung Cancer Summit Looking Ahead Panel: June 25, 2022

Educated Patient® Lung Cancer Summit Overcoming Barriers to Receiving Biomarker Testing Panel: June 25, 2022

Educated Patient® Lung Cancer Summit Advancements in Early-Stage Non-Small Cell Lung Cancer Presentation: June 25, 2022